Provided by Tiger Trade Technology Pte. Ltd.

Nexalin Technology, Inc.

7.23
-0.2700-3.60%
Post-market: 7.10-0.1300-1.80%16:10 EDT
Volume:31.32K
Turnover:213.48K
Market Cap:6.00M
PE:-0.52
High:7.69
Open:6.28
Low:6.25
Close:7.50
52wk High:60.00
52wk Low:6.25
Shares:829.40K
Float Shares:752.35K
Volume Ratio:0.08
T/O Rate:4.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.8684
EPS(LYR):-15.0475
ROE:-240.25%
ROA:-119.22%
PB:3.95
PE(LYR):-0.48

Loading ...

Nexalin Study Shows Strong Anxiety and Depression Response in Brazil Trial

MT Newswires Live
·
Jun 10

Nexalin Technology completes neurostimulation protocol trial

TIPRANKS
·
Jun 10

Nexalin reports 77.8% anxiety response rate in Brazil trial of DIFS neurostimulation device

Reuters
·
Jun 10

Nexalin Technology - No Serious Adverse Events or Seizures Reported in Nexalin Trial

THOMSON REUTERS
·
Jun 10

Nexalin Technology - Reports 77.8% Anxiety Response Rate at End of Treatment

THOMSON REUTERS
·
Jun 10

Nexalin Technology - Overall Quality of Life Improves Significantly at End of Treatment

THOMSON REUTERS
·
Jun 10

Nexalin Technology - Completes 8-Week Clinical Trial of 15 Ma, 77.5 Hz Neurostimulation in Anxiety

THOMSON REUTERS
·
Jun 10

Nexalin Technology Wins US Patent Protecting Neurostimulation Method Through 2042

MT Newswires Live
·
Jun 04

Nexalin wins US patent for dynamic frequency brain stimulation targeting anxiety, depression, insomnia

Reuters
·
Jun 04

Maxim Group Reaffirms Their Buy Rating on Nexalin Technology, Inc. (NXL)

TIPRANKS
·
May 21

Nexalin closes acquisition of PONM digital health platform for USD 1.3 million

Reuters
·
May 19

Nexalin Acquires AI-Integrated Digital Health Platform Behind Halo™ Clarity and Nexalin Neurocare™ Ahead of Planned FDA Pivotal Trial

THOMSON REUTERS
·
May 19

Nexalin Q1 FY26 net loss widens 5% to $2.1 million; revenue drops 64% to $14,950

Reuters
·
May 09

Nexalin Technology Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
May 08

Nexalin study shows insomnia improvement with 15 mA, 77.5 Hz brain stimulation

Reuters
·
Apr 28

Morgan Stanley Sticks to Their Buy Rating for Nuix Ltd. (NXL)

TIPRANKS
·
Apr 27

Nuix Ltd. (NXL) Gets a Buy from RBC Capital

TIPRANKS
·
Apr 24

BRIEF-Nexalin Technology Advances Clinical Trial Of HALO Clarity Toward Q2 2026 Enrollment

Reuters
·
Apr 22

Nexalin Technology enters agreements to advance HALO Clarity trial

TIPRANKS
·
Apr 22

Nexalin Technology Advances Pivotal Clinical Trial of Halo™ Clarity Toward Q2 2026 Enrollment

THOMSON REUTERS
·
Apr 22